US5688785A
(en)
*
|
1991-07-23 |
1997-11-18 |
Schering Corporation |
Substituted azetidinone compounds useful as hypocholesterolemic agents
|
US5631365A
(en)
*
|
1993-09-21 |
1997-05-20 |
Schering Corporation |
Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
|
MX9606319A
(es)
*
|
1994-06-20 |
1997-05-31 |
Schering Corp |
Compuestos de acetidinonas sustituidas utiles como agentes hipocolesterolemicos.
|
US6262277B1
(en)
*
|
1994-09-13 |
2001-07-17 |
G.D. Searle And Company |
Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
US6268392B1
(en)
|
1994-09-13 |
2001-07-31 |
G. D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
|
US6642268B2
(en)
|
1994-09-13 |
2003-11-04 |
G.D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
|
US5633246A
(en)
*
|
1994-11-18 |
1997-05-27 |
Schering Corporation |
Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
|
US5624920A
(en)
*
|
1994-11-18 |
1997-04-29 |
Schering Corporation |
Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
|
US5656624A
(en)
*
|
1994-12-21 |
1997-08-12 |
Schering Corporation |
4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
|
DK0862645T3
(da)
*
|
1995-09-27 |
2003-04-07 |
Schering Corp |
Stereoselektiv mikrobiel reduktionsproces
|
EP0766962A3
(de)
*
|
1995-10-03 |
2000-05-10 |
Beiersdorf-Lilly GmbH |
Behandlung der Atherosclerose
|
US5843938A
(en)
*
|
1995-10-03 |
1998-12-01 |
Beiersdorf-Lilly Gmbh |
Treatment of atherosclerosis
|
DE69621952T2
(de)
*
|
1995-10-31 |
2003-01-16 |
Schering Corp |
Zuckersubstituierte 2-azetidinone, verwendbar als hypocholesterdenische arzneimittel
|
AU7472896A
(en)
*
|
1995-11-02 |
1997-05-22 |
Schering Corporation |
Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-({phenyl or 4-fluorophenyl})-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinon
|
EP0939632B1
(de)
*
|
1996-02-23 |
2005-10-05 |
Eli Lilly And Company |
Non-peptidische vasopressin via antagonisten
|
US5739321A
(en)
*
|
1996-05-31 |
1998-04-14 |
Schering Corporation |
3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
|
US5886171A
(en)
*
|
1996-05-31 |
1999-03-23 |
Schering Corporation |
3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
|
US5756470A
(en)
*
|
1996-10-29 |
1998-05-26 |
Schering Corporation |
Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
|
FR2762336B1
(fr)
*
|
1997-04-21 |
1999-06-11 |
Francois Trantoul |
Procede de fabrication d'un film a motif non reproductible par lecture optique pour la protection de documents
|
US6133001A
(en)
*
|
1998-02-23 |
2000-10-17 |
Schering Corporation |
Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
|
US5919672A
(en)
*
|
1998-10-02 |
1999-07-06 |
Schering Corporation |
Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
|
CA2353981C
(en)
*
|
1998-12-07 |
2005-04-26 |
Schering Corporation |
Process for the synthesis of azetidinones
|
US6207822B1
(en)
|
1998-12-07 |
2001-03-27 |
Schering Corporation |
Process for the synthesis of azetidinones
|
PT1140184E
(pt)
*
|
1998-12-23 |
2003-10-31 |
Searle Llc |
Combinacoes de inibidores de proteina de transferencia de ester de colesterilo com derivados de acido nicotinico para indicacoes cardiovasculares
|
EP1140187B1
(de)
*
|
1998-12-23 |
2003-09-03 |
G.D. Searle LLC. |
Kombinationen einem ibat inhibitor und einem mtp inhibitor für kardiovaskuläre indikationen
|
US6569905B1
(en)
|
1998-12-23 |
2003-05-27 |
G.D. Searle, Llc |
Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
|
BR9916565A
(pt)
*
|
1998-12-23 |
2002-01-29 |
Searle Llc |
Combinações de inibidores do transporte ácido da bile ileal e derivados do ácido fìbrico para indicações cardiovasculares
|
IL143943A0
(en)
*
|
1998-12-23 |
2002-04-21 |
Searle Llc |
Combinations of ileal bile acid transport inhibitors and bile acid sequestering agents for cardiovascular indications
|
CA2356422C
(en)
|
1998-12-23 |
2008-09-16 |
G.D. Searle Llc |
Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
|
ATE242009T1
(de)
*
|
1998-12-23 |
2003-06-15 |
Searle Llc |
Kombinationen von cholesteryl ester transfer protein inhibitoren und fibronsäure derivaten für kardiovaskuläre indikationen
|
AU2157400A
(en)
|
1998-12-23 |
2000-07-31 |
G.D. Searle & Co. |
Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
|
AU3382699A
(en)
|
1999-04-05 |
2000-10-23 |
Schering Corporation |
Stereoselective microbial reduction for the preparation of - (4-fluorophenyl) - 3(r)-(3(s) - hydroxy-3 (4-fluorophenyl) propyl))-4(s) (4-hydroxyphenyl)-2-azetidinone
|
US6297268B1
(en)
|
1999-11-30 |
2001-10-02 |
Schering Corporation |
Imidazoles as cholesterol lowering agents
|
WO2001068096A2
(en)
*
|
2000-03-10 |
2001-09-20 |
Pharmacia Corporation |
Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
|
EP1286984A2
(de)
|
2000-03-10 |
2003-03-05 |
Pharmacia Corporation |
Verfahren zur herstellung von tetrahydrobenzothiepinen
|
US6584357B1
(en)
*
|
2000-10-17 |
2003-06-24 |
Sony Corporation |
Method and system for forming an acoustic signal from neural timing difference data
|
WO2002036124A2
(en)
*
|
2000-10-30 |
2002-05-10 |
Schering Corporation |
Treatment and method using loratadine and montelukast
|
EP1510521A1
(de)
*
|
2000-12-20 |
2005-03-02 |
Schering Corporation |
Zuckersubstituierte 2-Azetidinone Verwendbar als Hypocholesterdenische Arzneimittel
|
BR0116212A
(pt)
*
|
2000-12-20 |
2003-12-30 |
Schering Corp |
2-azetidinonas açúcar-substituìdas úteis como agentes hipocolesterolêmicos
|
US6982251B2
(en)
*
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
EP1593670B1
(de)
*
|
2000-12-20 |
2007-08-08 |
Schering Corporation |
Hydroxysubstituierte 2-Azetidinone verwendbar als Hypocholesterolemische Arzneimittel
|
IL156552A0
(en)
*
|
2000-12-21 |
2004-01-04 |
Aventis Pharma Gmbh |
Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
|
AU2002216097B2
(en)
*
|
2000-12-21 |
2006-09-07 |
Sanofi-Aventis Deutschland Gmbh |
Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
|
AU2006203175B2
(en)
*
|
2001-01-26 |
2008-07-24 |
Organon Llc |
Combinations of peroxisome proliferator-activated receptor (PPAR) activators(s) and sterol absorption inhibitors(s) and treatments for vascular indications
|
EP1911462A3
(de)
|
2001-01-26 |
2011-11-30 |
Schering Corporation |
Zusammensetzungen enthaltend einen Sterolabsorptionshemmer
|
DK1353694T3
(da)
*
|
2001-01-26 |
2008-03-25 |
Schering Corp |
Kombinationer af ezetimibe med aspirin til behandling af vaskulære tilstande
|
AU2006202618B2
(en)
*
|
2001-01-26 |
2007-04-19 |
Organon Llc |
Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
US7071181B2
(en)
*
|
2001-01-26 |
2006-07-04 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
|
KR20080077033A
(ko)
*
|
2001-01-26 |
2008-08-20 |
쉐링 코포레이션 |
혈관 질환을 치료하기 위한 스테롤 흡수 억제제와 심혈관제제의 조합물
|
AU2007201970B2
(en)
*
|
2001-01-26 |
2008-04-17 |
Organon Llc |
Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
CA2434033A1
(en)
*
|
2001-01-26 |
2002-08-01 |
Schering Corporation |
Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
IL156422A0
(en)
*
|
2001-01-26 |
2004-01-04 |
Schering Corp |
The use of substituted azetidinone compounds for the treatment of sitosterolemia
|
AU2002240050A1
(en)
*
|
2001-01-26 |
2002-08-06 |
Schering Corporation |
Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
|
AU2008201609B8
(en)
*
|
2001-01-26 |
2009-01-08 |
Organon Llc |
Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitors(s) and treatments for vascular indications
|
AU2002247019C1
(en)
*
|
2001-01-26 |
2017-05-11 |
Organon Llc |
Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
AU2005246926B2
(en)
*
|
2001-01-26 |
2008-02-28 |
Merck Sharp & Dohme Corp. |
The use of substituted azetidinone compounds for the treatment of sitosterolemia
|
TWI291957B
(en)
*
|
2001-02-23 |
2008-01-01 |
Kotobuki Pharmaceutical Co Ltd |
Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
|
SK287408B6
(sk)
|
2001-03-28 |
2010-09-07 |
Schering Corporation |
Spôsob prípravy medziproduktov na výrobu azetidinónov
|
AU2002308778A1
(en)
*
|
2001-05-25 |
2002-12-09 |
Schering Corporation |
Use of azetidinone substituted derivatives in the treatment of alzheimer's disease
|
US20040077625A1
(en)
*
|
2001-07-25 |
2004-04-22 |
Tremont Samuel J. |
Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
|
US7056906B2
(en)
|
2001-09-21 |
2006-06-06 |
Schering Corporation |
Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
|
PT1429756E
(pt)
*
|
2001-09-21 |
2007-01-31 |
Schering Corp |
Tratamento de xantoma com derivados de azetidinona como inibidores de absorção de esteróis
|
US20030119808A1
(en)
*
|
2001-09-21 |
2003-06-26 |
Schering Corporation |
Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
|
US7053080B2
(en)
*
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
SI1429756T1
(sl)
*
|
2001-09-21 |
2007-02-28 |
Schering Corp |
Zdravljenje ksantomov z azetidinonskimi derivati kot inhibitorji absorpcije sterola
|
CA2464685A1
(en)
*
|
2001-11-02 |
2003-05-15 |
G.D. Searle Llc |
Novel mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (asbt) and taurocholate uptake
|
CA2466081A1
(en)
*
|
2001-11-09 |
2003-05-15 |
Atherogenics, Inc. |
Methods of reversing and preventing cardiovascular pathologies
|
CN1596240A
(zh)
*
|
2001-12-19 |
2005-03-16 |
阿特罗吉尼克斯公司 |
查耳酮衍生物及其治疗疾病的用途
|
US7202247B2
(en)
|
2001-12-19 |
2007-04-10 |
Atherogenics, Inc. |
1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
|
FR2833842B1
(fr)
*
|
2001-12-21 |
2004-02-13 |
Aventis Pharma Sa |
Compositions pharmaceutiques a base de derives d'azetidine
|
MXPA04006255A
(es)
|
2002-01-17 |
2004-09-27 |
Pharmacia Corp |
Compuestos novedosos de alquil/aril hidroxi o ceto tiepina como inhibidores del transporte del acido biliar codependiente del sodio apical y la captacion de taurocolato.
|
WO2003074101A1
(en)
*
|
2002-02-28 |
2003-09-12 |
Eli Lilly And Company |
Method of treating atherosclerosis and hypercholesterolemia
|
US20040116510A1
(en)
*
|
2002-03-05 |
2004-06-17 |
Nichtberger Steven A. |
Antihypertensive agent and cholesterol absorption inhibitor combination therapy
|
US20030204096A1
(en)
*
|
2002-03-25 |
2003-10-30 |
Schering Corporation |
Enantioselective synthesis of azetidinone intermediate compounds
|
DE10227508A1
(de)
*
|
2002-06-19 |
2004-01-08 |
Aventis Pharma Deutschland Gmbh |
Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
GB0215579D0
(en)
*
|
2002-07-05 |
2002-08-14 |
Astrazeneca Ab |
Chemical compounds
|
JP4579681B2
(ja)
|
2002-07-09 |
2010-11-10 |
ブリストル−マイヤーズ スクイブ カンパニー |
抗糖尿病薬および抗肥満薬として有用な置換ヘテロシクロ誘導体および方法
|
US7135556B2
(en)
*
|
2002-07-19 |
2006-11-14 |
Schering Corporation |
NPC1L1 (NPC3) and methods of use thereof
|
US20040132058A1
(en)
|
2002-07-19 |
2004-07-08 |
Schering Corporation |
NPC1L1 (NPC3) and methods of use thereof
|
AR040588A1
(es)
*
|
2002-07-26 |
2005-04-13 |
Schering Corp |
Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
|
US6933292B2
(en)
*
|
2002-07-30 |
2005-08-23 |
Children's Medical Center Corporation |
Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors
|
WO2004056727A2
(en)
*
|
2002-12-19 |
2004-07-08 |
Atherogenics, Inc. |
Process of making chalcone derivatives
|
US7208486B2
(en)
|
2003-03-07 |
2007-04-24 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
WO2004081004A1
(en)
*
|
2003-03-07 |
2004-09-23 |
Schering Corporation |
Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
|
ES2311806T3
(es)
|
2003-03-07 |
2009-02-16 |
Schering Corporation |
Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
|
CN1805926A
(zh)
*
|
2003-05-05 |
2006-07-19 |
兰贝克赛实验室有限公司 |
二苯基氮杂环丁酮衍生物的反式异构体的制备方法
|
AR041089A1
(es)
|
2003-05-15 |
2005-05-04 |
Merck & Co Inc |
Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
|
KR20110117731A
(ko)
*
|
2003-05-30 |
2011-10-27 |
랜박시 래보러터리스 리미티드 |
치환된 피롤 유도체와 hmg―co 억제제로서의 이의 용도
|
WO2005000217A2
(en)
*
|
2003-06-06 |
2005-01-06 |
Merck & Co., Inc. |
Combination therapy for the treatment of dyslipidemia
|
WO2005009951A2
(en)
*
|
2003-07-24 |
2005-02-03 |
Merck & Co., Inc. |
Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use
|
WO2005009955A1
(en)
*
|
2003-07-31 |
2005-02-03 |
Hetero Drugs Limited |
Ezetimibe polymorphs
|
EP1522541A1
(de)
*
|
2003-10-07 |
2005-04-13 |
Lipideon Biotechnology AG |
Neue hypocholesterolemische Verbindungen
|
WO2005042692A2
(en)
*
|
2003-10-31 |
2005-05-12 |
Forbes Medi-Tech Inc. |
A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors
|
EP1918000A2
(de)
|
2003-11-05 |
2008-05-07 |
Schering Corporation |
Verbindungen aus lipidverändernden Wirkstoffen und substituierten Azetidinonen und Behandlungen für Gefäßzustände
|
CA2544309A1
(en)
*
|
2003-11-05 |
2005-05-26 |
Schering Corporation |
Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
|
PL380414A1
(pl)
*
|
2003-11-10 |
2007-01-22 |
Microbia, Inc. |
4-Diarylo-1- fenyloazetydyn-2-ony
|
WO2005049592A1
(en)
*
|
2003-11-24 |
2005-06-02 |
Hetero Drugs Limited |
A novel process for ezetimibe intermediate
|
EP1699759B1
(de)
*
|
2003-12-23 |
2010-10-20 |
AstraZeneca AB |
Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung
|
GB0329778D0
(en)
*
|
2003-12-23 |
2004-01-28 |
Astrazeneca Ab |
Chemical compounds
|
CN100471835C
(zh)
|
2003-12-23 |
2009-03-25 |
默克公司 |
抗高胆固醇血症化合物
|
WO2005069900A2
(en)
*
|
2004-01-16 |
2005-08-04 |
Merck & Co., Inc. |
Npc1l1 (npc3) and methods of identifying ligands thereof
|
CA2910191C
(en)
|
2004-03-05 |
2022-03-08 |
The Trustees Of The Univeristy Of Pennsylvania |
The use of mtp inhibitors for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
|
US20060211752A1
(en)
|
2004-03-16 |
2006-09-21 |
Kohn Leonard D |
Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
|
US20050244367A1
(en)
*
|
2004-05-03 |
2005-11-03 |
Ilypsa, Inc. |
Phospholipase inhibitors localized in the gastrointestinal lumen
|
MXPA06013456A
(es)
*
|
2004-05-21 |
2007-03-01 |
Sanofi Aventis Deutschland |
Metodo para producir derivados de 1,4-difenilazetidinona.
|
UA87854C2
(en)
|
2004-06-07 |
2009-08-25 |
Мерк Энд Ко., Инк. |
N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
|
WO2006004903A2
(en)
*
|
2004-06-28 |
2006-01-12 |
Atherogenics, Inc. |
1,2-bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
|
US20070244107A1
(en)
*
|
2004-08-25 |
2007-10-18 |
Waters M Gerard |
Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
|
US20060046996A1
(en)
|
2004-08-31 |
2006-03-02 |
Kowa Co., Ltd. |
Method for treating hyperlipidemia
|
PE20060594A1
(es)
*
|
2004-09-09 |
2006-08-18 |
Novartis Ag |
Composicion farmaceutica que contiene un agonista de ppar
|
US20060069080A1
(en)
*
|
2004-09-29 |
2006-03-30 |
Veltri Enrico P |
Combinations of substituted azetidinones and CB1 antagonists
|
CN102633730A
(zh)
|
2004-12-03 |
2012-08-15 |
先灵公司 |
作为cb1拮抗剂的取代哌嗪
|
MX2007007324A
(es)
*
|
2004-12-15 |
2007-07-09 |
Schering Corp |
Ensayos funcionales para los inhibidores de absorcion de colesterol.
|
US20130082232A1
(en)
|
2011-09-30 |
2013-04-04 |
Unity Semiconductor Corporation |
Multi Layered Conductive Metal Oxide Structures And Methods For Facilitating Enhanced Performance Characteristics Of Two Terminal Memory Cells
|
MX2007012253A
(es)
|
2005-04-04 |
2007-12-07 |
Univ Pontificia Catolica Chile |
Uso de ezetimibe para la prevencion y tratamiento de calculos de colesterol en la via biliar.
|
TW200726746A
(en)
*
|
2005-05-06 |
2007-07-16 |
Microbia Inc |
Processes for production of 4-biphenylylazetidin-2-ones
|
WO2006122117A2
(en)
*
|
2005-05-09 |
2006-11-16 |
Microbia, Inc. |
Organometal benzenephosphonate coupling agents
|
BRPI0608970A2
(pt)
*
|
2005-05-11 |
2010-02-17 |
Microbia Inc |
processos para produção de 4-bifenililazetidin-2-onas fenólicas
|
US7737155B2
(en)
|
2005-05-17 |
2010-06-15 |
Schering Corporation |
Nitrogen-containing heterocyclic compounds and methods of use thereof
|
AU2006249905A1
(en)
*
|
2005-05-25 |
2006-11-30 |
Microbia, Inc. |
Processes for production of 4-(biphenylyl)azetidin-2-one phosphonic acids
|
AU2006259646A1
(en)
*
|
2005-06-15 |
2006-12-28 |
Merck Sharp & Dohme Corp. |
Anti-hypercholesterolemic compounds
|
CA2610959A1
(en)
*
|
2005-06-20 |
2007-01-04 |
Schering Corporation |
Piperidine derivatives useful as histamine h3 antagonists
|
SA06270191B1
(ar)
*
|
2005-06-22 |
2010-03-29 |
استرازينيكا ايه بي |
مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
|
CA2613239A1
(en)
*
|
2005-06-22 |
2006-12-28 |
Manne Satyanarayana Reddy |
Improved process for the preparation of ezetimibe
|
AR054482A1
(es)
*
|
2005-06-22 |
2007-06-27 |
Astrazeneca Ab |
Derivados de azetidinona para el tratamiento de hiperlipidemias
|
EP1741427A1
(de)
*
|
2005-07-06 |
2007-01-10 |
KRKA, D.D., Novo Mesto |
Pharmazeutische Zusammensetzung enthaltend Simvastatin und Ezetimibe
|
US20070049748A1
(en)
*
|
2005-08-26 |
2007-03-01 |
Uppala Venkata Bhaskara R |
Preparation of ezetimibe
|
KR20070063592A
(ko)
|
2005-09-08 |
2007-06-19 |
테바 파마슈티컬 인더스트리즈 리미티드 |
에제티밉의 합성을 위한 중간체인(3r,4s)-4-((4-벤질옥시)페닐)-1-(4-플루오로페닐)-3-((s)-3-(4-플루오로페닐)-3-히드록시프로필)-2-아제티디논의제조 방법
|
TW200806623A
(en)
*
|
2005-10-05 |
2008-02-01 |
Merck & Co Inc |
Anti-hypercholesterolemic compounds
|
WO2007048027A2
(en)
|
2005-10-21 |
2007-04-26 |
Novartis Ag |
Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
|
US8026377B2
(en)
*
|
2005-11-08 |
2011-09-27 |
Ranbaxy Laboratories, Limited |
Process for (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
|
HU0501164D0
(en)
*
|
2005-12-20 |
2006-02-28 |
Richter Gedeon Vegyeszet |
New industrial process for the production of ezetimibe
|
MX2008008340A
(es)
*
|
2005-12-21 |
2008-09-03 |
Schering Corp |
Tratamiento de enfermedad de higado graso no alcoholica usando agentes reductores de colesterol y/o antagonista/agonista inverso de receptor de histamina 3.
|
EP1971573B1
(de)
*
|
2005-12-22 |
2009-10-14 |
Medichem S.A. |
Verfahren zur herstellung von zwischenprodukten für die herstellung von ezetimibe
|
CA2637565A1
(en)
|
2006-01-18 |
2007-07-26 |
Schering Corporation |
Cannibinoid receptor modulators
|
US7956182B2
(en)
*
|
2006-02-16 |
2011-06-07 |
Kotobuki Pharmaceutical Co., Ltd. |
Process for preparing optically active alcohols
|
EP1986489A2
(de)
|
2006-02-24 |
2008-11-05 |
Schering Corporation |
Npc1l1-orthologe
|
JP2009529055A
(ja)
*
|
2006-03-06 |
2009-08-13 |
テバ ファーマシューティカル インダストリーズ リミティド |
エゼチミベ組成物
|
WO2008020314A2
(en)
*
|
2006-03-14 |
2008-02-21 |
Ranbaxy Laboratories Limited |
Statin stabilizing dosage formulations
|
EP2004639A2
(de)
*
|
2006-04-10 |
2008-12-24 |
Teva Pharmaceutical Industries Ltd |
Verfahren zur synthese von azetinidon
|
TW200811098A
(en)
*
|
2006-04-27 |
2008-03-01 |
Astrazeneca Ab |
Chemical compounds
|
US20070275052A1
(en)
*
|
2006-05-24 |
2007-11-29 |
Glenmark Pharmaceuticals Limited |
Pharmaceutical compositions containing sterol inhibitors
|
EP2049102A4
(de)
*
|
2006-07-14 |
2010-12-22 |
Ranbaxy Lab Ltd |
Polymorphe formen eines hmg-coa-reduktasehemmers und verwendung
|
US20080058305A1
(en)
*
|
2006-08-29 |
2008-03-06 |
Vinod Kumar Kansal |
Processes for the purification of (3R,4S)-4-(4-hydroxy-protected-phenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-oxopropyl]azetidin-2-one
|
WO2008030382A1
(en)
*
|
2006-09-05 |
2008-03-13 |
Schering Corporation |
Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
|
CN101541795A
(zh)
*
|
2006-09-15 |
2009-09-23 |
先灵公司 |
用于治疗疼痛、糖尿病和脂类代谢紊乱的螺-稠合氮杂环丁烷衍生物
|
CN101528227A
(zh)
*
|
2006-09-15 |
2009-09-09 |
先灵公司 |
氮杂环丁酮衍生物及其使用方法
|
KR20090071589A
(ko)
|
2006-09-15 |
2009-07-01 |
쉐링 코포레이션 |
통증 및 지질 대사 장애의 치료에 유용한 아제티딘 및 아제티돈 유도체
|
EP2061792A2
(de)
*
|
2006-09-15 |
2009-05-27 |
Schering Corporation |
Azetidinon-derivate und verwendungsverfahren dafür
|
EP2066668A1
(de)
*
|
2006-09-15 |
2009-06-10 |
Schering Corporation |
Spirozyklische azetidinon-derivate zur behandlung von fettstoffwechselkrankheiten, schmerzen, diabetes und anderen erkrankungen
|
US20080085315A1
(en)
*
|
2006-10-10 |
2008-04-10 |
John Alfred Doney |
Amorphous ezetimibe and the production thereof
|
CN100564357C
(zh)
*
|
2006-10-20 |
2009-12-02 |
浙江天宇药业有限公司 |
一种氮杂环丁酮衍生物及其合成方法
|
US20100035857A1
(en)
*
|
2006-12-20 |
2010-02-11 |
Devita Robert J |
Anti-hypercholesterolemic compounds
|
EP1939174A1
(de)
*
|
2006-12-21 |
2008-07-02 |
LEK Pharmaceuticals D.D. |
Einschlusskomplex von Ezetimib und einem Cyclodextrin und Verfahren zu seiner Herstellung
|
EP2120927A1
(de)
*
|
2006-12-21 |
2009-11-25 |
Aegerion Pharmaceuticals, Inc. |
Verfahren zur behandlung von obesität mit einer kombination aus einem mtp-inhibitor und einem cholesterolabsorptionsinhibitor
|
CN102285906B
(zh)
*
|
2007-01-24 |
2014-11-19 |
克尔克公司 |
依泽替米贝的制备方法和其的衍生物
|
WO2008096372A2
(en)
*
|
2007-02-06 |
2008-08-14 |
Ind-Swift Laboratories Limited |
Process for preparing highly pure ezetimibe using novel intermediates
|
WO2008104875A1
(en)
*
|
2007-03-01 |
2008-09-04 |
Pfizer Products Inc. |
Oxazolidinones as cholesterol absorption inhibitors
|
US20100125059A1
(en)
|
2007-03-06 |
2010-05-20 |
Teijin Pharma Limited |
1-biarylazetidinone derivative
|
WO2008112166A2
(en)
|
2007-03-09 |
2008-09-18 |
Indigene Pharmaceuticals Inc. |
Combination of metformin r-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
|
WO2008123953A1
(en)
*
|
2007-04-02 |
2008-10-16 |
Merck & Co., Inc. |
Anti-hypercholesterolemic compound
|
US20100197564A1
(en)
*
|
2007-04-19 |
2010-08-05 |
Schering Corporation |
Diaryl morpholines as cb1 modulators
|
US8048880B2
(en)
*
|
2007-05-03 |
2011-11-01 |
Anthera Pharmaceuticals, Inc. |
Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
|
US20090047716A1
(en)
*
|
2007-06-07 |
2009-02-19 |
Nurit Perlman |
Reduction processes for the preparation of ezetimibe
|
US20080318920A1
(en)
*
|
2007-06-19 |
2008-12-25 |
Protia, Llc |
Deuterium-enriched ezetimibe
|
US20080319221A1
(en)
*
|
2007-06-22 |
2008-12-25 |
Bernd Junker |
Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
|
US20080319218A1
(en)
*
|
2007-06-22 |
2008-12-25 |
Andreas Haubrich |
Processes for Making and Using Benzyl Pentahydroxyhexylcarbamoylundecanoate
|
CA2692268A1
(en)
*
|
2007-06-28 |
2009-01-08 |
Intervet International B.V. |
Substituted piperazines as cb1 antagonists
|
EP2170847A2
(de)
*
|
2007-06-28 |
2010-04-07 |
Intervet International BV |
Substituierte piperazine als cb1-antagonisten
|
US20100204195A1
(en)
*
|
2007-07-27 |
2010-08-12 |
Cipla Limited |
Pharmaceutical Compositions and Process for Making Them
|
WO2009024889A2
(en)
|
2007-08-21 |
2009-02-26 |
Ranbaxy Laboratories Limited |
Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
|
WO2009032264A1
(en)
*
|
2007-08-30 |
2009-03-12 |
Teva Pharmaceutical Industries Ltd. |
Processes for preparing intermediates of ezetimibe by microbial reduction
|
WO2009027785A2
(en)
*
|
2007-08-30 |
2009-03-05 |
Pfizer Products Inc. |
1, 3-oxazole derivatives as cetp inhibitors
|
DE102007054497B3
(de)
*
|
2007-11-13 |
2009-07-23 |
Sanofi-Aventis Deutschland Gmbh |
Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
|
UA103179C2
(ru)
|
2007-12-10 |
2013-09-25 |
Ратиофарм Гмбх |
Фармацевтическая композиция, которая содержит эзетимиб
|
CZ305066B6
(cs)
*
|
2008-02-25 |
2015-04-22 |
Zentiva, K.S. |
Způsob výroby (3R,4S)-1-(4-fluorfenyl)-3-[(3S)-3-(4-fluorfenyl)-3-hydroxypropyl)]-4-(4-hydroxyfenyl)-2-azetidinonu
|
EP2128133A1
(de)
|
2008-05-26 |
2009-12-02 |
Lek Pharmaceuticals D.D. |
Ezetiminverfahren und -zusammensetzung
|
US20110077232A1
(en)
*
|
2008-06-06 |
2011-03-31 |
Nicox S.A. |
Compositions comprising atorvastatin 4-(nitrooxy) butyl ester and a hypolipidemic drug
|
US20090312302A1
(en)
*
|
2008-06-17 |
2009-12-17 |
Ironwood Pharmaceuticals, Inc. |
Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
|
US8273554B2
(en)
|
2008-08-29 |
2012-09-25 |
Codexis, Inc. |
Ketoreductase polypeptides for the stereoselective production of (4S)-3-[(5S)-5-(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one
|
CA2743434C
(en)
|
2008-11-14 |
2015-04-21 |
Bomi P. Framroze |
A method of lowering circulating oxidized low density lipoprotein-beta-2-glycoprotein 1 complex for treatment of atherosclerosis
|
EP2204170A1
(de)
|
2008-12-01 |
2010-07-07 |
LEK Pharmaceuticals D.D. |
Pharmazeutische Zusammensetzung mit Ezetimibe und Simvastatin
|
US20110245209A1
(en)
|
2008-12-16 |
2011-10-06 |
Schering Corporation |
Pyridopyrimidine derivatives and methods of use thereof
|
EP2379562A1
(de)
|
2008-12-16 |
2011-10-26 |
Schering Corporation |
Bicyclische pyranonderivate als agonisten am nicotinsäurerezeptor
|
EP2216016A1
(de)
|
2009-02-06 |
2010-08-11 |
LEK Pharmaceuticals d.d. |
Verfahren zur Herstellung einer pharmazeutischen Zusammensetzung, die Ezetimib umfasst
|
CA2754384A1
(en)
|
2009-03-06 |
2010-09-10 |
Lipideon Biotechnology Ag |
Pharmaceutical hypocholesterolemic compositions
|
ATE536172T1
(de)
|
2009-03-13 |
2011-12-15 |
Sanovel Ilac Sanayi Ve Ticaret As |
Ezetimibzusammensetzungen
|
US9040688B2
(en)
|
2009-03-31 |
2015-05-26 |
Lupin Limited |
Intermediates in the preparation of 1,4-diphenyl azetidinone
|
US9388440B2
(en)
|
2009-04-01 |
2016-07-12 |
Mylan Laboratories Limited |
Enzymatic process for the preparation of (S)-5-(4-fluoro-phenyl)-5-hydroxy-1morpholin-4-yl-pentan-1-one, an intermediate of Ezetimibe and further conversion to Ezetimibe
|
WO2011002424A2
(en)
|
2009-07-02 |
2011-01-06 |
Bilgic Mahmut |
Solubility and stability enchancing pharmaceutical formulation
|
EP2448564A2
(de)
|
2009-07-02 |
2012-05-09 |
Bilgic Mahmut |
Löslichkeitsverstärkende pharmazeutische formulierung
|
EP2448919A2
(de)
|
2009-07-02 |
2012-05-09 |
Mahmut Bilgic |
Löslichkeits- und stabilitätsverstärkende pharmazeutische formulierung
|
CN101993403B
(zh)
|
2009-08-11 |
2012-07-11 |
浙江海正药业股份有限公司 |
氮杂环丁酮类化合物及医药应用
|
SG178456A1
(en)
|
2009-08-19 |
2012-04-27 |
Codexis Inc |
Ketoreductase polypeptides for the preparation of phenylephrine
|
WO2011106548A1
(en)
|
2010-02-24 |
2011-09-01 |
Relypsa, Inc. |
Amine polymers for use as bile acid sequestrants
|
BR112012021444A2
(pt)
|
2010-02-24 |
2016-05-31 |
Relypsa Inc |
polímero de amina reticulado, composição farmacêutica, método de redução do colesterol ldl sérico em um indivíduo, métodos para tratar doença, de remoção de sais biliares de um indivíduo, e para melhorar o controle glicêmico em um indivíduo, e, processo para preparar o polímero de aminas.
|
US20130189215A1
(en)
|
2010-02-24 |
2013-07-25 |
Relypsa, Inc. |
Polyimidazoles for use as bile acid sequestrants
|
EP2368543A1
(de)
|
2010-03-25 |
2011-09-28 |
KRKA, tovarna zdravil, d.d., Novo mesto |
Verfahren zur Herstellung einer granulierten pharmazeutischen Zusammensetzung mit Simvastatin und/oder Ezetimibe
|
CA2796607C
(en)
|
2010-04-23 |
2019-09-10 |
Synageva Biopharma Corp |
Lysosomal storage disease enzyme
|
US9040262B2
(en)
|
2010-05-04 |
2015-05-26 |
Codexis, Inc. |
Biocatalysts for ezetimibe synthesis
|
ES2372460B1
(es)
|
2010-07-09 |
2012-11-16 |
Moehs Ibérica S.L. |
Nuevo método para la preparación de ezetimiba.
|
BR112013005673B1
(pt)
|
2010-09-09 |
2020-12-15 |
Alexion Pharmaceuticals, Inc |
Uso de lipase ácida lisossomal (lal) humana recombinante no tratamento da deficiência de lipase ácida lisossomal
|
RS60901B1
(sr)
|
2010-11-08 |
2020-11-30 |
Albireo Ab |
Ibat inhibitori za lečenje oboljenja jetre
|
WO2012064267A1
(en)
|
2010-11-08 |
2012-05-18 |
Albireo Ab |
A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
|
WO2012076030A1
(en)
|
2010-12-10 |
2012-06-14 |
Pharmathen S.A. |
Process for the preparation of intermediate compounds useful in the preparation of ezetimibe
|
KR20140006037A
(ko)
|
2011-02-15 |
2014-01-15 |
시나게바 바이오파르마, 코포레이션 |
리소좀의 산 리파제 결핍을 치료하는 방법들
|
US8455474B2
(en)
|
2011-03-04 |
2013-06-04 |
Mackay Memorial Hospital |
Method for treating tuberculosis
|
WO2012155932A1
(en)
|
2011-05-17 |
2012-11-22 |
Pharmathen S.A. |
Improved process for the preparation of ezetimibe
|
PL231215B1
(pl)
|
2011-06-15 |
2019-02-28 |
Inst Chemii Organicznej Polskiej Akademii Nauk |
Sposób wytwarzania podstawionych azetydynonów oraz związków pośrednich do ich syntezy
|
CN102675177A
(zh)
*
|
2011-06-28 |
2012-09-19 |
常州制药厂有限公司 |
一种降血脂药物及其关键中间体的制备方法
|
CN102952055A
(zh)
*
|
2011-08-16 |
2013-03-06 |
凯瑞斯德生化(苏州)有限公司 |
一种依泽替米贝和其中间体的制备方法
|
CN103204795B
(zh)
*
|
2012-01-11 |
2016-12-14 |
重庆华邦胜凯制药有限公司 |
一种手性氮杂环丁酮类化合物的制备方法
|
ES2802252T3
(es)
|
2012-05-01 |
2021-01-18 |
Althera Life Sciences Llc |
Formulación de comprimido oral que consiste en la combinación fija de rosuvastatina y ezetimiba para el tratamiento de hiperlipidemia y enfermedades cardiovasculares
|
CN103570574B
(zh)
|
2012-07-20 |
2016-04-13 |
中国科学院上海有机化学研究所 |
一种依泽替米贝的合成方法及该方法中所用的中间体
|
CN103102297A
(zh)
*
|
2012-09-28 |
2013-05-15 |
北京赛林泰医药技术有限公司 |
一种新的依折麦布的合成方法
|
TW201427658A
(zh)
|
2012-12-10 |
2014-07-16 |
Merck Sharp & Dohme |
藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
|
CN103864708A
(zh)
*
|
2012-12-12 |
2014-06-18 |
天津市医药集团技术发展有限公司 |
一种依折麦布中间体的制备方法
|
WO2015039675A1
(en)
|
2013-09-23 |
2015-03-26 |
Pharmathen S.A. |
Novel process for the preparation of ezetimibe intermediates
|
WO2015066252A1
(en)
|
2013-11-04 |
2015-05-07 |
Merck Sharp & Dohme Corp. |
Glucagon receptor antagonist compounds, compositions thereof, and methods of use
|
US9926269B2
(en)
|
2013-12-18 |
2018-03-27 |
Rudjer Boskovic Institute |
Beta-lactam cholesterol absorption inhibitors
|
CN103739537B
(zh)
*
|
2013-12-24 |
2015-05-20 |
连云港恒运医药科技有限公司 |
依折麦布的新合成方法
|
KR20150079373A
(ko)
|
2013-12-30 |
2015-07-08 |
한미약품 주식회사 |
에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
|
CN103755616A
(zh)
*
|
2013-12-31 |
2014-04-30 |
北京万全德众医药生物技术有限公司 |
一种制备依泽替米贝异构体的方法
|
SG11201609050UA
(en)
|
2014-05-30 |
2016-12-29 |
Pfizer |
Carbonitrile derivatives as selective androgen receptor modulators
|
CN105294426B
(zh)
*
|
2014-06-09 |
2019-05-14 |
浙江海正药业股份有限公司 |
氮杂环丁酮化合物制备方法及其中间体
|
CN104447474A
(zh)
*
|
2014-11-11 |
2015-03-25 |
武汉武药科技有限公司 |
一种依折麦布异构体的合成方法
|
CN104387308A
(zh)
*
|
2014-11-18 |
2015-03-04 |
武汉福星生物药业有限公司 |
一种控制EZ-zanOH杂质产生制备高纯度依折麦布的方法
|
CN104513187B
(zh)
*
|
2015-01-09 |
2017-05-31 |
安润医药科技(苏州)有限公司 |
依折麦布及其中间体的合成方法
|
JP2016145173A
(ja)
*
|
2015-02-09 |
2016-08-12 |
株式会社トクヤマ |
(3r,4s)‐1‐(4‐フルオロフェニル)‐[3(s)‐ヒドロキシ‐3‐(4‐フルオロフェニル)プロピル]‐(4‐ヒドロキシフェニル)‐2‐アゼチジノンの製造方法
|
CN114099496A
(zh)
|
2015-03-13 |
2022-03-01 |
艾斯柏伦治疗公司 |
含etc1002和依泽替米贝的组合及治疗方法
|
MA41793A
(fr)
|
2015-03-16 |
2018-01-23 |
Esperion Therapeutics Inc |
Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
|
CN105287513A
(zh)
*
|
2015-10-23 |
2016-02-03 |
浙江永宁药业股份有限公司 |
一种依折麦布药物组合物及其制备方法
|
CN107098841A
(zh)
*
|
2016-02-19 |
2017-08-29 |
常州方楠医药技术有限公司 |
一种依折麦布的制备方法及该方法中所用的中间体
|
CN109791797B
(zh)
|
2016-12-05 |
2023-05-02 |
智慧芽信息科技(苏州)有限公司 |
在大数据库中根据化学结构相似性搜索和显示可用信息的系统、装置和方法
|
US20180338922A1
(en)
|
2017-05-26 |
2018-11-29 |
Esperion Therapeutics, Inc. |
Fixed dose formulations
|
EP3437636A1
(de)
|
2017-08-02 |
2019-02-06 |
Adamed sp. z o.o. |
Pharmazeutische zusammensetzung mit ezetimibe
|
US11408274B2
(en)
|
2018-01-16 |
2022-08-09 |
Q.E.D. Environmental Systems, Inc. |
Fluid level monitoring system and method incorporating pressure sensor system having inflatable/collapsible bag
|
EP3942047A1
(de)
|
2019-03-20 |
2022-01-26 |
Regeneron Pharmaceuticals, Inc. |
Behandlung von erhöhten lipidspiegeln mit sterol-regulator-bindenden protein bindenden protein (scap) inhibitoren
|
CN113727732B
(zh)
|
2019-03-20 |
2023-08-08 |
雷杰纳荣制药公司 |
用固醇调节元件结合转录因子1(srebf1)抑制剂治疗脂质水平升高
|
BR112022001783A2
(pt)
|
2019-07-31 |
2022-03-22 |
Tecnimede Soc Tecnico Medicinal Sa |
Composições orais sólidas multiunitárias de liberação imediata, seus métodos e usos.
|
EP4188338A1
(de)
|
2020-07-27 |
2023-06-07 |
KRKA, d.d., Novo mesto |
Zweischichtige tablette mit ezetimib und atorvastatin
|
AU2022291920A1
(en)
*
|
2021-06-17 |
2023-12-21 |
Zhejiang Hisun Pharmaceutical Co., Ltd. |
Hybutimibe intermediate and preparation method therefor
|
WO2023275715A1
(en)
|
2021-06-30 |
2023-01-05 |
Pfizer Inc. |
Metabolites of selective androgen receptor modulators
|